Controlling lipid levels in diabetes

Acta Diabetologica

Volumn 39, Issue SUPPL. 2, 2002, Pages

  Taskinen, M R ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Coronary heart disease; Diabetic dyslipidaemia; Lipid lowering; Low density lipoprotein; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; FEMALE; HUMAN; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK REDUCTION;

CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPERLIPIDEMIAS; LIPIDS; RISK FACTORS;

EID: 0036942723     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920200023     Document Type: Conference Paper

References (31)

1. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB (1988) Mortality among diabetics in a national health sample. Am J Epidemiol 128:389-401
2. Kereiakes DJ (1985) Myocardial infarction in the diabetic patient. Clin Cardiol 8:446-450
3. Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemalä M, Haffner SM, Pyörälä K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69-75
4. Ledru F, Ducimetière P, Battaglia S, Courbon D, Beverelli F, Guize L, Guermonprez J-L, Diéblod B (2001) New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol 37:1543-1550
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Risk Group (1993) Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
6. Lehto S, Ronnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M (1997) Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
8. Syvänne M, Taskinen MR (1997) Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350[Suppl 1]:20-23
9. Sniderman AD, Scantlebury T, Clanflone K (2001) Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447-459
10. American Diabetes Association (2002) Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 25:S74-S77
11. Demacker PN, Veerkamp MJ, Bredie SJ, Marcovina SM, de Graaf J, Stalenhoef AF (2000) Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 153:483-490
12. Harris MI (2000) Health care and health status and outcome for patients with type 2 diabetes. Diabetes Care 23:754-758
13. Marcelino JJ, Feingold KR (1996) Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 100:605-610
14. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689
15. American Diabetes Association (2002) Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 25:S50-S60
16. American Diabetes Association (2002) Diabetes mellitus and exercise (Position Statement). Diabetes Care 25:S64-S68
17. Tan CE, Chew LS, Chio LF, Tai ES, Lim HS, Lim SC, Jayakumar L, Eng HK, Packard CJ (2001) Cardiovascular risk factors and LDL subfraction profile in type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract 52:107-114
18. Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1-10
19. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: a double-blind randomized placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341
20. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
21. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E (1998) Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 97:1446-1452
22. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
24. Gmerek A, McLain R, Nawrocki J (1997) A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin-dependent diabetes mellitus. Diabetes 46[Suppl 1]:363A
25. LaRosa JC for the TNT Steering Committee (1998) Effect of lowering LDL-C beyond currently recommended minimum targets - the Treating to New Targets (TNT) study. In: Thirteenth International Symposium on Drugs Affecting Lipid Metabolism, 30 May-3 June 1998, Florence, Italy (abstract)
26. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
27. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K (1999) Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159:2661-2667
28. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K (1999) Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 11:1771-1778
29. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR (2001) How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 24:45-50
30. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arrnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
31. Pyörälä K, Pederson TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G for the Scandinavian Simvastatin Survival study (4S) Group (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620